MeSH D011655 - pulmonary embolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Taro Pharmaceutical | Warfarin | Warfarin |  | 1999-07-15 |  |  |
| LEO Pharma | Tinzaparin | Innohep |  | 2000-07-14 |  |  |
| Mylan | Apixaban | Apixaban |  | 2019-12-23 |  |  |
| Fondaparinux | Arixtra |  | 2001-12-07 |  |  | |
| Heparin | Heparin |  | 2017-11-30 |  |  | |
| Rivaroxaban | Rivaroxaban Viatris (previously Rivaroxaban Mylan) |  | 2021-11-12 |  |  | |
| Dabigatran etexilate | Dabigatran Etexilate |  | 2025-02-03 |  |  | |
| Johnson & Johnson | Rivaroxaban | Xarelto | 2024-08-28 | 2011-07-01 | $2,373 M | Y2024 |
| GSK | Fondaparinux | Quixidar |  | 2002-03-21 |  |  |
| Cipla | Warfarin | Warfarin |  | 2011-05-25 |  |  |
| Sandoz | Enoxaparin | Enoxaparin |  | 2010-07-23 |  |  |
| Heparin | Heparin |  | 2011-06-08 |  |  | |
| Boehringer Ingelheim | Dabigatran etexilate | Pradaxa | 2023-06-14 | 2010-10-19 |  |  |
| Aspen Global | Heparin | Liquaemin |  | 1982-01-01 |  |  |
| Organon | Phenprocoumon | Liquamar |  | 1982-01-01 |  |  |
1
2
3
4
5
6
...
8
>
Clinical Trials
Historical Success Rate
Phase 1
82%9/11
Phase 2
94%16/17
Phase 3
86%42/49
Approved: 22Overall Success rate: 66%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use